Search

everythinglearnresearchcommunity

for

Search:↓

Deleting the MAD2L1 gene in mice led to rapid tumor growth despite chromosomal instability.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

Baricitinib may effectively treat oral lichen planus.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

Dicentrine reduced heart disease risk factors in rats, T-588 protected mice brains without side effects, Provir blocked herpes virus and lessened mouse symptoms, and LY191704 could treat hair loss and prostate issues.

Finasteride significantly reduced tics and obsessive-compulsive symptoms in Tourette syndrome patients.

Hair color loss can indicate the effectiveness of a drug targeting the KIT protein in mice and humans.

Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.

Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

A woman's hair turned white after taking a cancer drug called dasatinib.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Loss of the Y chromosome and UTY gene activity increases cancer risk in men.

Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.

Tsc2-deficient stem cells can help understand and treat TSC-related tumors.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

JAK inhibitors show promise for treating alopecia areata but their effectiveness and safety are still debated.

Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.

YH0618 helps reduce chemotherapy-induced hair loss by targeting specific proteins and pathways.